Treatment of hematologic malignancies is increasingly complex. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of breakthrough advances. In addition, targeted therapies and oral treatments bring the latest benefits to patients. This Congress focuses on the new approaches that have been incorporated into patient management, including the use of drugs, biologics, and diagnostics.
This congress is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with hematologic malignancies.
Optimal Management of CML without Breaking the Bank
Molecular Monitoring in CML: Known Knowns, Known Unknowns, and Unknown Unknowns
Current Management of Adult ALL
Chimeric Antigen Receptor (CAR) Modified T Cells for ALL
Management of Hodgkin Lymphoma in the Elderly
Targeted Therapy in Indolent Lymphoma
Debate: Is there a role for upfront transplant in the current management of symptomatic multiple myeloma?
The Continuum of MGUS and Smoldering Myeloma: When to Treat?
Molecular Prognostication in CLL from FISH to Next Generation Sequencing: Implications for Clinical Management
Changing Paradigms in the Management of CLL
Updates on the Prevention and Treatment of Cancer-Related Infections
Myeloid Growth Factors Revistited
Evolving Therapy of Mantle Cell Lymphoma: Is there still a role for upfront transplant?
Diffuse Large B Cell Lymphoma: Treatment Beyond R-CHOP
Debate: Follicular Lymphoma and the Role of Maintenance Therapy
Role of Molecular Advances in the Classification and Prognosis of MDS
AML: Current Management
Physicians The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.
NCCN designates this live activity for a maximum of 8.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Nurses The National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This activity is accredited for 8.75 contact hours of continuing education for nurses.
Accreditation as a provider refers to recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 8.75 CE contact hour(s). Activity code C00011657. Approval number 140001675.
This program supports 8.75 CE hours and has been assigned the following event number: 2014-145.
National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Follicular Lymphoma and the Role of Maintenance Therapy
A statement of credit will be issued only upon receipt of a completed activity evaluation form/ immediate post test.
There are early bird registration fees for physicians, nurses, pharmacists, and other healthcare-related professionals who register before August 15, 2014. Please refer to the fees page for specific information.
There is a registration fee of $699 for Industry if registered before September 18, 2014. The on-site registration fee for Industry is $749.
Faculty Disclosure All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
NCCN Americans with Disabilities Act Statement The NCCN Conferences and Meetings Department will be glad to assist registrants with any special needs as identified in the Americans with Disabilities Act. Please contact us at 215.690.0265215.690.0265 or email@example.com prior to this congress/conference with your exact needs or requirements.
NCCN.org – For Clinicians | NCCN.org/patients – For Patients
National Comprehensive Cancer Network | 275 Commerce Drive | Suite 300 | Fort Washington | PA | 19034 | US | 215.690.0300